StockData

Palisade Bio vs VivoSim Labs

PALI and VIVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PALI and VIVS compare

Palisade Bio is the larger company, worth 459 times as much as VivoSim Labs ($176M against $384K).

Palisade Bio keeps more of each dollar of sales as profit, with a net margin of −6388% compared with −11016% at VivoSim Labs.

Palisade Bio scores higher on the StockData Score (7 against 5 for VivoSim Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPALIVIVS
Size and price
Market cap$176M$384K
Share price$1.01$0.120
Change, 1 year−52.8%−94.5%
Change, 5 years−99.9%−99.8%
Beta (5Y)1.152.58
Employees100K15
StockData Score
Total score7 (better)5
Valuation score11
Growth score00
Performance score1 (better)0
Health score5 (better)4
Dividend score00
Valuation
P/S352×3.4× (better)
P/B1.4×–
FCF yield–−2639%
Growth
Revenue growth (TTM)–−21.1%
Profitability
Operating margin−7070% (better)−10117%
Net margin−6388% (better)−11016%
FCF margin–−9038%
Return on equity−51.4% (better)−343%
Financial health
Debt / equity0.00–
Interest coverage−4418.6×−944.3× (better)
Current ratio24.26 (better)1.70
Altman Z-score19.21 (better)−139.28
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−74.7% (better)−781%
Shareholder yield−74.7% (better)−781%
Ownership
Held by institutions99.5%3.2%
Held by insiders4.7%–
Insider net buying, 12 months−$124K$2.8K (better)
Short interest, % of float17.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.